{
  "pmcid": "12475902",
  "sha256": "2de7599004b31846b72bcbbdbff17d53b850b9e24ec7768f5e2b68fe24082add",
  "timestamp_utc": "2025-11-09T23:40:15.938146+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.859654188349843,
    "reading_ease": 15.752707738794697,
    "word_count": 259
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Multicentre Randomised Controlled Trial Comparing Olanexidine and Chlorhexidine-Alcohol for Surgical-Site Antisepsis"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This multicentre, randomised, open-label, blinded-endpoint controlled trial was conducted across five Japanese hospitals."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible participants were adults undergoing elective clean-contaminated gastrointestinal and hepatobiliary-pancreatic surgeries."
      },
      "Intervention": {
        "score": 2,
        "evidence": "This study aimed to compare the efficacy of aqueous olanexidine with chlorhexidine-alcohol in preventing SSIs."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare the efficacy of aqueous olanexidine with chlorhexidine-alcohol in preventing SSIs."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the 30-day SSI rate."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using a web-based system with block randomisation, and allocation was concealed."
      },
      "Blinding": {
        "score": 2,
        "evidence": "open-label, blinded-endpoint controlled trial"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From January 2023 to November 2023, 700 patients were randomised: 350 to the olanexidine group and 350 to the chlorhexidine-alcohol group."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "In the full analysis set, 347 patients in the olanexidine group and 345 in the chlorhexidine-alcohol group were analysed."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The 30-day SSI rate was 12.3% in the olanexidine group and 13.6% in the chlorhexidine-alcohol group (adjusted risk ratio 0.911, 95% CI 0.625 to 1.327; P = 0.626)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse effects were reported in 0.6% of the olanexidine group and 0.9% of the chlorhexidine-alcohol group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: UMIN 000049712."
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was independently conducted by Keio University."
      }
    },
    "total_score": 24,
    "max_score": 25
  }
}